San Jose BioCube now offers 15 new wet labs in the heart of Silicon Valley, located inside the just-completed Q Bay Center, a 112,232-square-foot innovation center near Levi® Stadium.

San Jose BioCube provides all the resources we need to run our operations with less capital and greater efficiencies. Being able to expand within the facility without space constraints has been instrumental to our success, too.

SAN JOSE, Calif. (PRWEB)
February 26, 2020

San Jose BioCube, a long-established life sciences incubator, announced the availability of 15 move-in-ready wet labs designed for high-potential life sciences startups. Dubbed “BioCube North,” the incubator is housed on the ground floor of the Q Bay Center, the 112,232-square-foot facility at 160 East Tasman Drive in San Jose.

Since 2004, the legacy of improving life through discovery has been deeply rooted at San Jose BioCube. The headquarters, located at 5941 Optical Court, San Jose, spans approximately 37,000 square feet and is currently home to 24 startups. The company’s master plan is to change the world by providing a resource-rich infrastructure and community where scientists can thrive.

With a multi-billion-dollar track record of nurturing nascent startups and supporting scores of commercialized discoveries, BioCube continues to foster next waves of great ideas that will rival past graduate disruptors such as Impossible Foods, Ariosa Diagnostics (acquired by Roche), Collagen Solutions (AIM: COS), Genia Technologies (acquired by Roche), Aridis Pharmaceuticals (NAS: ARDS), and Geneweave (acquired by Roche), to name a few.

“The San Francisco Bay Area is a top science and research hub because there are three major universities and scores of global companies that attract top scientists and technicians from around the world,” said Oscar Battaglia, director of operations at BioCube San Jose. “Our objective is to provide access to all this talent and a launchpad for the next wave of biotech, cleantech, and life-sciences success stories.”

“Today, the life sciences incubator submarket is the most in-demand sector in the Bay Area,” said David Klein, SVP at Transwestern San Francisco and BioCube’s top advisor. “While estimates peg demand at approximately 6mm square feet of incubator space, the current inventory of 750,000 square feet is consistently 100 percent leased with waiting lists. So, we wanted to help fulfill lab space needs because when researchers have a space to hatch new ideas, we all win.”

Launching in March, BioCube North’s labs will offer over 5,000 square feet of shared space where life-sciences startups have the appropriate plumbing, ventilation, refrigeration and equipment, together with BioCube’s global standard of facility management and client care, to grow their businesses.

“San Jose BioCube provides all the resources we need to run our operations with less capital and greater efficiencies,” said Julia Kirshner, CEO of zPredicta. “Being able to expand within the facility without space constraints has been instrumental to our success, too.”

QBay’s amenities available to BioCube clients include bench, cubicle, single office, office suite and conference room availability, off-street parking, access to events, workshops, gym, barbeque, outdoor amenity space, and a theater for all-hands meetings.

Highlights of the new BioCube facility:

• Ground floor lab space in a 112,232-square-feet newly built research and innovation center
• Located in Tech Triangle Corridor with easy access to routes 237-101-880 and across from Santa Clara Bay Pointe light rail station
• Offers gym, cafe, on-demand office areas, common conference rooms, and outdoor amenities
• Near LEVI Stadium, retail stores, coffee bars, restaurants, and new residential communities
• Connection to HEDA Investment Co. Ltd. (Hangzhou Economic and Development) with $500 million available for life-sciences investment

Facilities and leasing contact:

Oscar Battaglia – 408.960.3807 – info@sanjosebiocube.com

About Q Bay Center

Q Bay Center, founded by Hangzhou Overseas Center Inc., is a Silicon-Valley-based platform to connect and support innovation and entrepreneurship. With a tripartite mission of “Platform + Investment + Services”, Q Bay Center is designed as an innovative business model which combines real property, business exhibition, financial activity, technology cooperation, business services and startup incubation. By leveraging the synergy of technology, finance, industrial ecology and culture, the center is committed to enhancing connection and empowering development.

About San Jose BioCube

In everything we do, we believe in making the world a better place for innovators by providing user-friendly workspaces, modern labs and common areas that are as clean and safe as they are beautifully designed and maintained. We thrill at providing care and all the little things that help accelerate and commercialize profound discoveries. Located in South San Jose, the original BioCube incubator is already home to some of the most dynamic early-stage companies that are pushing the limits of life sciences. For more information, visit: sanjosebiocube.com.

Share article on social media or email:

“This genomic landscape of Ectodermal Dyplasias helps us understand the molecular drivers of ectodermal dysplasias. We can use the data to find…new discoveries that will lead to better treatments of the disease.”

ANN ARBOR, Mich. (PRWEB)
February 26, 2020

Genomenon®, home of the Mastermind® Genomic Search Engine, is celebrating Rare Disease Week 2020 by making the comprehensive genomic landscape of Ectodermal Dysplasias (ED) freely available to clinical and pharma researchers. The release of this data set will provide genetic insight for doctors and researchers searching for efficacious treatments for ED, a collection of more than 100 different disorders that affect the teeth, skin, sweat glands, hair, nails, and other ectodermal structures.

The National Foundation for Ectodermal Dysplasias (NFED), the worldwide expert on ectodermal dysplasias, is the only advocacy organization in the United States dedicated to those living with these disorders. They offer a range of educational resources and events to meet the changing needs of those affected by the different types of ectodermal dysplasias and provide support and community for families with ED.

Genomenon founder Dr. Mark Kiel was diagnosed with ectodermal dysplasia at age 13, which led to a connection with NFED and, ultimately, to his chosen career as an MD, PhD in molecular genetic pathology. Once Genomenon was able to produce data that could help NFED in their search for treatments and a cure, he reached out to offer assistance.

The Genomenon team produced a Mastermind Genomic Landscape(TM) for the primary causative genes associated with ectodermal dysplasias, which included comprehensive evidence for 2,908 genetic mutations (variants), 112 unique clinical symptoms, annotated functional studies, and photos of the physical hallmarks of the ED disorders. They then presented the database to NFED.

“This genomic landscape of Ectodermal Dyplasias helps us understand the molecular drivers of ectodermal dysplasias. We can use the data to find correlations between genes, variants and the disease pathways, and find new discoveries that will lead to better treatments of the disease.” Said Mary Fete, executive director of NFED.

Expanding the body of knowledge on a disease requires access to all of the currently published medical and genetic literature on the disease. Unfortunately, finding this information can be like looking for a needle in a haystack. With the current publication rate at about 3 million articles a year, any rare disease makes up an extremely minute portion of this mass of literature. Mastermind’s Artificial Intelligence and Machine Learning processes find all of the available evidence and present it for researchers and clinicians, ensuring the best possible outcomes.

In 2019, Genomenon produced the Genomic Landscape for rare disease Beta-Propeller Protein-Associated Neurodegeneration (BPAN), making it available to researchers as the first in their rare disease efforts of this kind.

Read the BPAN Press Release

About Genomenon

Genomenon is a genomic health IT company whose mission is to ensure that every rare disease patient is accurately diagnosed and properly treated. With over 7,000 rare diseases impacting more people combined than cancer and a $262 billion orphan drug market targeting rare diseases, Genomenon delivers the genomic tools and data needed to diagnose and treat the genetic drivers of each rare disease.

The Mastermind Genomic Search Engine is used by hundreds of genetic labs worldwide to accelerate diagnosis, increase diagnostic yield, and assure repeatability in reporting genetic testing results.

Mastermind Genomic Landscapes inform pharmaceutical and bio-pharma companies on precision medicine development, deliver genomic biomarkers for clinical trial target selection, and support CDx regulatory submissions with empirical evidence.

Genomenon was named 2020 Global Company of the Year in Clinical Genomic Interpretation by Frost & Sullivan.

For more information, visit Genomenon.com

Share article on social media or email:

Steven Lang

Dr. Lang’s technical expertise in discovery and development as well as his track record in creating innovative and dynamic teams will be invaluable in building on Aragen’s growth.

MORGAN HILL, Calif. (PRWEB)
February 25, 2020

Aragen Bioscience is pleased to announce the appointment of Dr. Steven Lang as Vice President, Biologics. Aragen, a wholly-owned subsidiary of GVK BIO, is a leading Contract Research Organization focused on accelerating biologics product development with an integrated offering that includes antibody discovery and humanization, stable cell line development, recombinant protein production and purification, and differentiated diseases models.

“It’s my pleasure to welcome Dr. Steven Lang to Aragen.” said Axel Schleyer, CEO, Aragen Bioscience. “The addition of Dr. Lang is part of Aragen’s ongoing investment in our team, facilities and technologies. This multiyear expansion in our capabilities has included adding over 15,000 square feet of laboratory space, introducing our proprietary RapTr™ Cell Line Development services and adding mass spectrometry to our analytical tool set. Dr. Lang’s technical expertise in discovery and development as well as his track record in creating innovative and dynamic teams will be invaluable in building on Aragen’s growth.”

Prior to joining Aragen, Dr. Lang was with Genentech’s Cell Culture department as a Director overseeing research material generation, cell line development, automation, and CHO process development covering activities from DNA to Phase 2 clinical supplies. In addition to his functional role, he led an initiative to modernize the CMC scientific data management processes. This work spawned numerous digitization efforts across the global Roche Technical Development network to drive efficiency, transparency and compliance. He also acted as a CMC leader for a project team delivering an innovative bispecific antibody into clinical trials.

Prior to Genentech, Dr. Lang was with Janssen Research and Development where he built the analytical discovery, stability screening and cell line development groups into important interfaces between discovery and development. He brought experience in biologics discovery, technology development, process optimization, project leadership, due diligence and strategic interactions. At Johnson & Johnson, he had roles spanning pre-clinical, early development, regulatory filings and late-stage/marketed product support as a functional and CMC project leader.

Dr. Lang received his PhD in Molecular Microbiology from State University of New York Stony Brook. He then undertook post-doctoral work at Stony Brook and Johnson & Johnson Pharmaceutical R&D. He received his MBA from Rider University.

About Aragen Bioscience, Inc.

Aragen Bioscience, Inc., a wholly owned subsidiary of GVK BIO, is a leading contract research organization based in the San Francisco Bay Area. Aragen Bioscience offers a diverse set of In Vitro and In Vivo services for the discovery, characterization, activity assessment and early development of biologic and diagnostic products.

Share article on social media or email:

OceanGate’s 5-person Submersible, Cyclops 1

The Hudson Canyon is on the scale of the Grand Canyon and lies just off the coast of New York City yet remains shrouded in mystery.

EVERETT, Wash. (PRWEB)
February 20, 2020

OCEANGATE EXPEDITIONS ANNOUNCES DIVE MISSIONS INTO THE FABLED HUDSON CANYON, scheduled for August 2020 in a state-of-the-art, 5-person deep-sea submersible. Adventurous explorers will join oceanographic scientists and researchers on missions to explore one of the world’s most biodiverse habitats and seek to uncover previously undiscovered sea-life, shipwrecks and sites.

This undersea adventure expedition is the first of its kind to explore the alien world beneath the waves deep within the Hudson Canyon. Participants, known as mission specialists, will work side-by-side with a team of subsea experts and researchers to discover what lies at the edge of the continental shelf.

“Hudson Canyon is one of the least explored undersea areas and yet sea-life thrives here,” shares Stockton Rush, CEO, OceanGate. “It’s amazing that the Hudson Canyon is on the scale of the Grand Canyon and it lies just off the coast of New York City, and remains shrouded in mystery. The expedition will take citizen explorers places no human has directly observed before. We are anxious to see what we will discover together,” explains Rush.

Aspiring mission specialists interested in joining the Hudson Canyon Deep-Sea Discovery Expedition should contact OceanGate for qualifications, availability and additional details. To obtain more information about all upcoming OceanGate expeditions, visit http://www.oceangateexpeditions.com.

Share article on social media or email:

MSK Ultrasound Injection Training March 12, 2020 (888) 998-6343

The ultrasound guided injection course does not involve animal meat or cadavers. We have real patients there with real pathology, so the experience is totally hands on!

LAS VEGAS (PRWEB)
February 19, 2020

The nation’s leader in MSK Ultrasound Injection Training, R3 Medical, announced today the course specials for the upcoming March 12th training in Las Vegas. Not only will each attendee receive a complimentary regenerative procedure, but also $500 off an ultrasound machine purchase (new machines).

When it comes to performing joint injections, using ultrasound guidance is amazingly efficient and helpful for providers. The reason is that ultrasound guided injections are not only accurate, but the machines are small so they are very portable.

The ultrasound course is hands on, with real patients coming in to receive real procedures. Said R3 CEO David Greene, MD, MBA, “The ultrasound guided injection course does not involve animal meat or cadavers. We have real patients there with real pathology, so the experience is totally hands on! Our expert trainers have over 20 years experience each. The skills learned will be useful immediately.”

When it comes to deciding which ultrasound machine to purchase, it can be very confusing. This way providers get to see and work with several types of units and see which one they are comfortable with.

The full day course covers both large and small joints, and the cost is only $845 (normally $895). Each provider receives an exosome injection if desired, which makes the course pay for itself!

R3 Medical Training is the nation’s leader in hands on courses. In addition to the ultrasound injection training, they also offer a PDO thread lift training course along with multiple stem cell training courses.

To sign up online, visit https://mskultrasoundcourse.com and for more information call (888) 998-6343.

Share article on social media or email:

Markus Spanner is Managing Director of PI Worldwide, as of January 2020

“Our technologies have enormous potential to make our customers’ applications even more successful,” says Markus Spanner.

KARLSRUHE, Germany (PRWEB)
February 19, 2020

At Physik Instrumente (PI) GmbH & Co. worldwide headquarters in Karlsruhe, Germany, a long-planned generational change has been implemented in its management. “Our technologies have enormous potential to make our customers’ applications even more successful,” says Markus Spanner, who has been PI’s managing director since the beginning of 2020 after holding managerial responsibility as Managing Director, Finance & Controlling at PI for the past 11 years. “PI has a great deal of potential for growth that we want to exploit in the future more than ever before.”

In his new role, Markus Spanner has established an extended management team to take a structured approach to achieving the new targets. He will be assisted by Dr. Peter Schittenhelm (COO), Dr. Markus Czanta (CTO), Stéphane Bussa (CSO), and Heiko Brehm (CFO).

Physik Instrumente employs more than 1,300 people all over the world and is represented at 15 locations in Europe, North America, and Asia. The company is a market and technology leader for high-precision positioning in high-tech business sectors such as life sciences, semiconductor manufacturing, photonics, and industrial automation. PI occupies third place in the Handelsblatt’s Top 100 Ranking of SMEs 2019.

PI USA congratulates Markus Spanner!

Learn about PI’s products»

https://www.pi-usa.us/en/products/

USA / Canada

http://www.pi-usa.us | info@pi-usa.us | (508) 832-3456

> READ the PI Tech Blog

> WATCH PI Videos on YouTube

> FOLLOW PI on Twitter

> CONNECT on LinkedIn

Share article on social media or email:

Red Nucleus

“We are witnessing a burgeoning demand for services in Japan from our global clients.” Ian Kelly, Red Nucleus CEO

YARDLEY, Pa. (PRWEB)
February 19, 2020

Red Nucleus, a leading provider of strategic learning, performance, and process solutions for the life sciences industry, today announced the opening of a new office in Tokyo, Japan. The new office will be headed by Kenji Nagamura, Associate Partner, Red Nucleus R&D.

Red Nucleus announced the new office in response to customer requests for regional coverage. Customers headquartered in Japan and global customers with Japanese affiliates have interacted with the Red Nucleus team in other regions and are looking for similar support in Japan.

Ian Kelly, Red Nucleus CEO, stated, “The opening of the Tokyo office is an exciting development for us. We are witnessing a burgeoning demand for services in Japan from our global clients. With Kenji’s leadership, we can offer direct access to the expertise and knowledge of a respected industry veteran. Kenji’s deep knowledge of Japanese regulations and business practices will help us to expand quickly and fully support our global customer base. We are looking forward to delivering the same level of support that our clients have come to expect in other regions.”

Mr. Nagamura brings over 30 years of substantial experience in regulatory strategy and operations, non-clinical and clinical to his role. He has fostered good relationships with Japan PMDA and led cross-functional and interregional teams in the implementation of Regulatory Information Management systems, Global Electronic Document Management systems, and eCTD Publishing systems. He is also experienced in developing and maintaining IDMP data submission readiness programs.

Kenji Nagamura, Red Nucleus R&D Associate Partner, added, “I am excited to represent Red Nucleus R&D in Japan. We are already planning some local executive briefings that will provide significant value to our local customers and help them to shape their R&D operational strategies in the coming year.”

The new office location is:

Shinagawa East One Tower 4F

2-16-1 Konan, Minato-ku, Tokyo

108-0075, Japan

About Red Nucleus

Red Nucleus is the premier provider of strategic learning, performance, and process solutions exclusively for the life sciences industry. Our global solutions engage and inspire teams across the commercial and R&D spaces and are designed to boost understanding, efficacy, and compliance.

Squarely focused on the life sciences industry for more than 25 years, Red Nucleus takes pride in our long-term relationships with industry leaders, as well as our strategic partnerships with innovative startups. We are focused on developing thoughtful, high-quality solutions that are in accordance with each client’s unique culture and process. Our clients trust us to build impactful, award-winning programs that deliver actionable insights and measurable results.

Visit http://www.rednucleus.com to learn more.

Share article on social media or email:

FARMINGTON, Conn. (PRWEB)
February 18, 2020

Shoreline Biome, a microbiome research company that develops tools for characterizing microbiome populations down to the strain level, recently unveiled a novel DNA isolation product.

Shoreline Rapid Prep is a fast and easy-to-use kit designed for efficient and unbiased isolation of high molecular weight (HMW) single-stranded DNA (ssDNA) in excess of 40 kB from Gram-negative bacteria, Gram-positive bacteria, and fungi in microbiome samples, cell suspensions, or cell pellets. The ssDNA output is ideal for downstream PCR applications targeting specific bacterial or fungal genes of interest.

The lysis/DNA purification protocol (patent pending) ensures that no microbe is left behind, without the need for cumbersome bead beating, while preserving DNA integrity.

The features of the kit include:

• 
  Ideal for stool samples and bacterial and vegetative fungal cell isolates
• Fast and easy: 96 samples ready for PCR in less than 40 minutes
• Simple automation-ready workflow
• Superior lysis with no bead beating
• HMW ssDNA ideal for PCR applications targeting microbial or fungal genes of interest.

The Shoreline Complete line of kits are all-in-one kits that contain the Rapid Prep reagents and all reagents necessary for targeting the V4, V1-V3, V1-V9 or 16S-23S regions for Illumina or PacBio sequencing.

About Shoreline Biome:

Characterizing the human microbiome and analyzing its role in human health and disease are priority goals for researchers around the world. Shoreline Biome accelerates breakthroughs in microbiome research by developing transformative discovery tools that characterize microbiome populations down to the strain level. With Shoreline Biome products, all it takes is three easy steps: lyse, purify, and amplify. Shoreline Biome’s easy-to-use companion analysis software and comprehensive reference database enables straightforward strain-level identification and quantitation of all bacteria in the sample. To learn more, visit shorelinebiome.com.

Share article on social media or email: